title: Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
abstract: Cancer has been reported to be more common among kidney transplant recipients than waiting-list patients or the general population. Use of anticalcineurin agents and azathioprine are relevant risk factors. Nine renal allograft recipients (seven men and two women) of mean age 67.6 (55-77) years and mean time after transplantation of 30.7 (58-216) months were switched to everolimus-based immunosuppression because of the presence of biopsy-proven malignancies (eight patients) or neurological tacrolimus toxicity (one patient). One patient with posttransplant lymphoproliferative disease also received chemotherapy with a good evolution at 6 months. He showed an initial increase in the protein to creatinine ratio (peak 3.3 mg/mg at 3 months) that was controlled by increasing the enalapril dose. One patient with skin cancer and severe atheromatosis (baseline SCr 2.5 mg/dL, creatinine clearance 17 mL/min, and protein to creatinine ratio 3.2 mg/mg), had cyclosporine and everolimus overlapped for 25 days, showing a continued poor evolution requiring dialysis initiation at 3 months after switch. The other six patients with recurrent skin cancers had good cancer evolution, with no new skin tumors and regression of skin lesions in three, including not biopsied actinic keratosis. Sudden switching from calcineurin inhibitors to everolimus is safe and may be used in long-term transplant recipients with malignancies. In patients with advanced chronic nephropathy this approach appeared to be less beneficial.
authors.affiliation: Department of Nephrology, Hospital Ramón y Cajal, Madrid, Spain. afernandezr.hrc@salud.madrid.org
authors.forename: A
authors.initials: A
authors.lastname: Fernández
authors.forename: R
authors.initials: R
authors.lastname: Marcén
authors.forename: J
authors.initials: J
authors.lastname: Pascual
authors.forename: C
authors.initials: C
authors.lastname: Galeano
authors.forename: J
authors.initials: J
authors.lastname: Ocaña
authors.forename: E M
authors.initials: EM
authors.lastname: Arellano
authors.forename: C
authors.initials: C
authors.lastname: Alfaro
authors.forename: J J
authors.initials: JJ
authors.lastname: Villafruela
authors.forename: F J
authors.initials: FJ
authors.lastname: Burgos
authors.forename: J
authors.initials: J
authors.lastname: Ortuño
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002102:Cadaver; D065095:Calcineurin Inhibitors; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000453:epidemiology*; D012008:Recurrence; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus